Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): Involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography–mass spectrometry
Andreas H. Ewalda, Michael Puetzb and Hans H. Maurera, ,
aDepartment of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Kirrberger Strasse 1, D-66421 Homburg (Saar), Germany
bBundeskriminalamt, KT 34-Forensic Toxicology, D-65173 Wiesbaden, Germany
Received 25 October 2007; accepted 29 November 2007. Available online 8 December 2007.
The designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP) is known to be extensively metabolized in various species. The current study showed that cytochrome P450 2D6 was the only isoenzyme involved in formation of the main metabolite hydroxy DOM. In addition, the authors’ systematic toxicological analysis (STA) procedure using full-scan GC–MS was suitable to prove an intake of a common drug users’ dose of DOM by detection of hydroxy DOM in rat urine. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of DOM in human urine. However, DOM and/or other metabolites such as deamino-oxo-hydroxy DOM might be the target analyte in urine of CYP2D6 poor metabolizers.
Keywords: 2,5-Dimethoxy-4-methyl-amphetamine; DOM; STP; Designer drug; GC–MS; CYP2D6